曹杏;沈雷;张伟东;李林;陈振辉;

• 1:南阳市中心医院
• 2:郑州大学第三附属医院

摘要(Abstract)：

目的观察盐酸托莫西汀联合执行障碍康复训练治疗小儿多动症(ADHD)的临床疗效。方法纳入2018-01-2019-12在南阳市中心医院接受治疗的92例小儿多动症患儿,观察组和对照组各46例。对照组予以盐酸哌甲酯治疗并接受执行障碍康复训练,观察组予以盐酸托莫西汀治疗并接受执行障碍康复训练,比较2组临床疗效。结果观察组总有效率(91.3%)显著高于对照组(71.7%),差异有统计学意义(χ²=4.168,P=0.032)。治疗后2组多动症Conners儿童行为评定量表评分显著下降,但观察组下降更为突出,患儿认知功能提升显著。观察组不良反应率(17.4%)显著低于对照组(39.1%),差异有统计学意义(χ2=4.168,P=0.032)。治疗后2组多动症Conners儿童行为评定量表评分显著下降,但观察组下降更为突出,患儿认知功能提升显著。观察组不良反应率(17.4%)显著低于对照组(39.1%),差异有统计学意义(χ²=4.466,P<0.05)。结论盐酸托莫西汀联合执行障碍康复训练治疗小儿多动症效果显著,可显著改善患儿的认知能力,且具有良好的安全性。

关键词(KeyWords)： 多动症;小儿;盐酸托莫西汀;盐酸哌甲酯;康复训练;执行障碍

Abstract:

Keywords:

基金项目(Foundation): 河南省医学科技攻关计划项目（编号：2018020174）

作者(Authors): 曹杏;沈雷;张伟东;李林;陈振辉;

参考文献(References)：

• [1]SHARMA A,COUTURE J.A review of the pathophysiology,etiology,and treatment of attention-deficit hyperactivity disorder(ADHD)[J].Ann Pharmacother,2014,48(2):209-225.
• [2]CORTESE S,COGHILL D.Twenty years of research on attention-deficit/hyperactivity disorder(ADHD):looking back,looking forward[J].Evid Based Ment Health,2018,21(4):173-176.
• [3]THAPAR A,COOPER M.Attention deficit hyperactivity disorder[J].Lancet,2016,387(10024):1240-1250.
• [4]LI Y J,XIE X N,XUE L,et al.Global prevalence of obesity,overweight and underweight in children,adolescents and adults with autism spectrum disorder,attention-deficit hyperactivity disorder:A systematic review and meta-analysis[J].Obes Rev,2020,21(12):e13123.
• [5]MARTINEZ B J,MARTINEZ R J.Who says this is a modern disorder?The early history of attention deficit hyperactivity disorder[J].World J Psychiatry,2015,5(4):379-386.
• [6]D'AGATI E,CURATOLO P,MAZZONE L.Comorbidity between ADHD and anxiety disorders across the lifespan[J].Int J Psychiatry Clin Pract,2019,23(4):238-244.
• [7]REALE L,BARTOLI B,CARTABIA M,et al.Comorbidity prevalence and treatment outcome in children and adolescents with ADHD[J].Eur Child Adolesc Psychiatry,2017,26(12):1443-1457.
• [8]GERMANO E,GAGLIANO A,CURATOLO P.Comorbidity of ADHD and dyslexia[J].Dev Neuropsychol,2010,35(5):475-493.
• [9]CAYE A,SWANSON J M,COGHILL D,et al.Treatment strategies for ADHD:an evidence-based guide to select optimal treatment[J].Mol Psychiatry,2019,24(3):390-408.
• [10]COLVIN M K,STERM T A.Diagnosis,evaluation,and treatment of attention-deficit/hyperactivity disorder[J].J Clin Psychiatry,2015,76(9):e1148.
• [11]ENRIQUEZ-GEPPERT S,SMIT D,PIMENTA M G,et al.Neurofeedback as a Treatment Intervention in ADHD:Current Evidence and Practice[J].Curr Psychiatry Rep,2019,21(6):46.
• [12]WENTHUR C J.Classics in Chemical Neuroscience:Methylphenidate[J].ACS Chem Neurosci,2016,7(8):1030-1040.
• [13]WEIBEL S,MENARD O,LONITA A,et al.Practical considerations for the evaluation and management of Attention Deficit Hyperactivity Disorder(ADHD) in adults[J].Encephale,2020,46(1):30-40.
• [14]PERUGI G,PALLUCCHINI A,RIZZATO S,et al.Current and emerging pharmacotherapy for the treatment of adult attention deficit hyperactivity disorder(ADHD)[J].Expert Opin Pharmacother,2019,20(12):1457-1470.
• [15]LIANG E F,LIM S Z,TAM W W,et al.The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder(ADHD):Systematic Review,Meta-Analysis,and Meta-Regression[J].Int J Environ Res Public Health,2018,15(8):1789.
• [16]GROB S,FIGGE C,MATTHIES S,et al.ADHD in adulthood:Diagnostics and therapy[J].Nervenarzt,2015,86(9):1171-1178.
• [17]BREM S,GRüNBLATT E,DRECHSLER R,et al.The neurobiological link between OCD and ADHD[J].Atten Defic Hyperact Disord,2014,6(3):175-202.
• [18]POSNER J,POLANCZYK G V,SONUGA-BARKE E.Attention-deficit hyperactivity disorder[J].Lancet,2020,395(10222):450-462.
• [19]GRIFFITHS K R,LEIKAUF J E,TSANG T W,et al.Response inhibition and emotional cognition improved by atomoxetine in children and adolescents with ADHD:The ACTION randomized controlled trial[J].JPsychiatr Res,2018,102:57-64.
• [20]SCIBERRAS E,MULRANEY M,SILVA D,et al.Prenatal Risk Factors and the Etiology of ADHD-Review of Existing Evidence[J].Curr Psychiatry Rep,2017,19(1):1.
• [21]SAUER J M,RING B J,WITCHER J W.Clinical pharmacokinetics of atomoxetine[J].Clin Pharmacokinet,2005,44(6):571-590.
• [22]BROWN J T,BISHOP J R.Atomoxetine pharmacogenetics:associations with pharmacokinetics,treatment response and tolerability[J].Pharmacogenomics,2015,16(13):1513-1520.
• [23]杜振峰，蔡琛.计算机辅助认知训练联合作业治疗对脑卒中认知障碍患者的康复研究[J].中国实用神经疾病杂志，2020,23(23):2074-2080.
• [24]顾力华，陈奇刚，刘朵，等.作业治疗对脑卒中后偏瘫患者日常生活活动能力的影响[J].中国实用神经疾病杂志，2020,23(17):1539-1543.
• [25]CALLAHAN P M,PLAGENHOEF M R,BLAKE D T,et al.Atomoxetine improves memory and other components of executive function in young-adult rats and aged rhesus monkeys[J].Neuropharmacology,2019,155:65-75.
• [26]张勇，翟红印，郭智宽，等.免疫调节疗法对脑瘫儿童神经运动发育影响的临床研究[J].中国实用神经疾病杂志，2019,22(10):121-126.
• [27]张姝妤.康复训练与A型肉毒毒素对痉挛性脑瘫患儿肌张力恢复及日常生活能力的影响[J].中国实用神经疾病杂志，2019,22(22):2515-2520.
• [28]YU G,LI G F,MARKOWITZ J S.Atomoxetine:AReview of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition[J].J Child Adolesc Psychopharmacol,2016,26(4):314-326.